Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Eric Easom Insider Profile
4 Followers
Eric Easom, CEO, Director at AN2 Therapeutics, Inc., holds 1.36M shares in AN2 Therapeutics, Inc. (Ticker: ANTX). Most recently, Eric Easom Bought $50,000 shares of AN2 Therapeutics, Inc. on Nov 18, 2024 for an estimated value of 49.50K.
Eric Easom has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Roles
CEO, Director
Roles that Eric Easom holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:May 15, 2023 - May 15, 2024
Return:-58.30%
The most profitable trade made by Eric Easom
Eric Easom's Trading History
List of latest transactions for each holding click on a transaction to see Eric Easom's performance on stock
You May Also Like
Eric Easom insider profile FAQ
What is the percentage of profitable transactions made by Eric Easom?
The percentage of profitable transactions made by Eric Easom is ―.
What is the average return per transaction made by Eric Easom?
The average return per transaction made by Eric Easom is ―.
What stocks does Eric Easom hold?
Eric Easom holds: ANTX stocks.
What was Eric Easom’s latest transaction?
Eric Easom latest transaction was an Informative Buy of $49.50K.
What was Eric Easom's most profitable transaction?
Eric Easom’s most profitable transaction was an Informative Buy of ANTX stock on May 15, 2023. The return on the trade was -58.30%.
What is Eric Easom's role in AN2 Therapeutics, Inc.?
Eric Easom's role in AN2 Therapeutics, Inc. is CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.